We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
- Authors
Mercier, Frederic; Passot, Guillaume; Bonnot, Pierre-Emmanuel; Cashin, Peter; Ceelen, Wim; Decullier, Evelyne; Villeneuve, Laurent; Walter, Thomas; Levine, Edward A.; Glehen, Olivier; PSOGI Working Group; Ahrendt, S. A.; Akaishi, E.; Baik, S. H.; Baratti, D.; Bhatt, A.; De Hingh, I.; De Simone, M.; Dubé, P.; Edwards, R. P.
- Abstract
Purpose: Peritoneal carcinomatosis from appendiceal goblet cell carcinoma (A-GCC) is a rare and aggressive form of appendiceal tumor. Cytoreductive surgery (CRS) and hyperthermic intra peritoneal chemotherapy (HIPEC) was reported as an interesting alternative regarding survival compared to surgery without HIPEC and/or systemic chemotherapy. Our aim was to evaluate the impact of CRS and HIPEC for patients presenting A-GCC through an international registry. Methods: A prospective multicenter international database was retrospectively searched to identify all patients with A-GCC tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). The post-operative complications, long-term results, and principal prognostic factors were analyzed. Results: The analysis included 83 patients. After a median follow-up of 47 months, the median overall survival (OS) was 34.6 months. The 3- and 5-year OS was 48.5% and 35.7%, respectively. Patients who underwent complete macroscopic CRS had a significantly better survival than those treated with incomplete CRS. The 5-year OS was 44% and 0% for patients who underwent complete, and incomplete CRS, respectively (HR 9.65, p < 0.001). Lymph node involvement and preoperative chemotherapy were also predictive of a worse prognosis. There were 3 postoperative deaths, and 30% of the patients had major complications. Conclusion: CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of A-GCC origin, especially when complete CRS is achieved. Ideally, randomized control trials or more retrospective data are needed to confirm CRS and HIPEC as the gold standard in this pathology.
- Subjects
HYPERTHERMIC intraperitoneal chemotherapy; PERITONEAL cancer; CYTOREDUCTIVE surgery; APPENDIX (Anatomy); CANCER chemotherapy; NEOADJUVANT chemotherapy
- Publication
World Journal of Surgery, 2022, Vol 46, Issue 6, p1336
- ISSN
0364-2313
- Publication type
Article
- DOI
10.1007/s00268-022-06498-w